Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

A life-extending prostate cancer drug is to be made available to thousands of men in England in a matter of weeks, after a ...

Treatment with Leuprorelin did not improve OS or disease-specific survival for patients with nonmetastatic, high-risk prostate cancer who have undetectable PSA levels, while causing more adverse ...

A multitargeted T-cell therapy produced encouraging activity in a preliminary study of patients with pancreatic cancer, ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

Charity hails ‘momentous’ decision to give abiraterone to about 8,000 newly diagnosed men each year ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...